NeuroScientific Biopharmaceuticals Limited, often referred to as NeuroScientific, is a pioneering biopharmaceutical company headquartered in Australia. Founded in 2015, the company focuses on developing innovative treatments for neurological disorders, positioning itself at the forefront of the biopharmaceutical industry. With a strong emphasis on research and development, NeuroScientific is dedicated to advancing its core products, including its proprietary drug candidates aimed at addressing conditions such as chronic pain and neurodegenerative diseases. The company’s unique approach combines cutting-edge science with a commitment to improving patient outcomes, setting it apart in a competitive market. NeuroScientific has achieved significant milestones, including successful clinical trials and partnerships that enhance its market presence. As it continues to expand its operational reach, NeuroScientific remains committed to delivering transformative therapies that address unmet medical needs.
How does NeuroScientific Biopharmaceuticals Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
NeuroScientific Biopharmaceuticals Limited's score of 14 is lower than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.
NeuroScientific Biopharmaceuticals Limited, headquartered in Australia, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and climate commitments suggests that NeuroScientific Biopharmaceuticals may not yet have established a formal framework for addressing its carbon footprint or engaging in sustainability initiatives. As the biopharmaceutical industry increasingly prioritises environmental responsibility, it will be essential for the company to consider developing and implementing strategies to measure and reduce its carbon emissions in the future.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
NeuroScientific Biopharmaceuticals Limited is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.